## CRITICAL PATHWAYS IN HEAD AND NECK CANCER

Caroline Nickel, MS CCC-SLP Baylor University Medical Center Dallas, Texas


### **DISCLOSURES**


Caroline Nickel is employed by Baylor Institute for Rehabilitation. Caroline has no other financial disclosures or non-financial disclosures.




### OBJECTIVES

- ${}^{\bullet}$  To identify different steps of the pre-treatment pathway
- To identify role of different medical professionals who are part of the multidisciplinary team and pre-operative preparation period.
- Describe the role of the tumor board meeting with the establishment of care.
- Identify general goals for a pre-operative counseling session with the SLP







### **CLINICAL PRESENTATION**

- Recurrence of Cancer noted on a surveillance visit (1-5 year post treatment)
   Completed radiation treatment—yet persistent disease( Radiation resistant)

- persistent disease (Kadiation resistant)
  (hemi-lar)ngectony)—now with recurrence.
  Non-functional larynx (trach and g-tube dependent)
  Chronic aspiration (refractory to treatment)



# WORK-UP

### DL +PAN-ENDO

- Laryngoscopy/Esophagoscopy/bronchoscopy
- Determine Esophageal & Post-cricoid involvement
- Palpate Crico-arytenoid Joint for mobility (fixed-?T3)
- Palpate thickness/volume/Depth of invasion (DOI)





### CT NECK (+ CONTRAST)

Analyze key anatomical structures: Laryngeal cartilages (thyroid; cricoid; aryrenoid)/Laryngeal Ventricular Complex/Anterior & Posterior Commissure/Paraglottic Space/Pre-Epiglottic Space



### CT NECK (+ CONTRAST)

- Important for T-staging; sizing tumor volume and staging nodal disease.
- A recurrent cancer may be discovered on a surveillance scan. Caution must be used on post treatment scans after CRT to rule out recurrence/residual tissue vs. changes post RT treatment.



### CT CHEST + CONTRAST

- Analyze to identify lung nodules consistent with metastatic disease.
   If I node is identified—maybe resectable (MI-disease)
- presence of multiple nodes would change treatment course to "systemic" therapy or chemo-therapy with more palliative intent.



# PET SCAN A positron emission tomography (PET) scan uses a special dye with radioactive tracers that illuminate chemical hyper metabolic activy of organs May include infection or inflammation and certain types of hymhoid tissue. Often used compared to CT Useful to find Metastatic disease Likeful in finding other unknown Useful in finding other unknown "primary" tumors Must be carefully interpreted to avoid "false" positive findings of non-cancerous things. Do BEFORE biopsy-biopsy sites will "light" up on PET

### LABORATORY TESTING

Important for pre-surgical planning and needed by the Hemo/Onc team for chemo-therapy planning.

- Complete blood count (CBC): hemoglobin; red vs white blood cells)
- Basic Metabolic Panel (BMP): glucose; electrolyte; kidney
   Liver FunctionTests (LFTs)

- Coagulation Function (Coags)
   Pre-Albumin/Albumin (nutrition labs)
   Thyroid Stimulating Hormone (TSH)
   Hep C/ HIV

### TUMOR STAGING

- \* Most common universal staging system: American Joint Committee on Cancer (AJCC) International Union for Cancer Control (UICC): TNM system \*\*New guidelines came out 2017\*\*
- p16+,HPV algorithm for oropharyngeal cancers
   Extra-Nodal Extension (ENE)
- NMSC H&N category
- Based on 3 clinical features and clinical categories are assigned:TNM –Tumor; Nodes; Metastasis
- Categories are collected and combined in a process called stage grouping to assign an overall stage
   Stage is determined when cancer is 1<sup>st</sup> diagnosed and doesn't change (Stage II that metastasizes later vs. Stage IV)

### UNIVERSAL TUMOR STAGING TNM

- 3 basic clinical features:
  - the size; depth of invasion; structures involved (in centimeters) of the primary tumor (T)
  - the presence, number, size, and spread (unilateral or bilateral) to the regional lymph nodes (N)



# T-STAGING FOR LARYNGEAL AND SUPRA-GLOTTIC TUMORS (NEGATIVE FOR HR-HPV)

- TIS Carcinoma in situ
  TI Tumor limited to vocal cord with normal mobility (may involve anterior and posterior commissure (2 cm or less)
- TIA limited to one TVF TIB involving Both TVF
- T2 Tumor extension to supra and or subglottic with impaired vocal cord mobility (<2 cm but not more than 4 cm)

- T4 B: tumor invading prevertebral space, encasing carotid artery, or invading mediastinal structures

- TI-tumor confined to one supraglottic subsite with normal vocal cord mobility

- cord mobility
  T2-fumor invades mucosa in more
  than one supragloctic subsite, without
  TVF fixation
  T3-fumor ilmited to laryns, with TVF
  fixation and or invasion of post
  cricid area or pre-epiplostic space
  T4A-fumor invading through thyroid
  cardiage and or other extra laryngeal
  trasses, stray muscles, thyroid,
  esophagus)
  T4B Unresectable:tumor invading
- T4B Unresectable:tumor invading prevertebral space, encasing carotid artery, or invading mediastinal structures

### NODAL DISEASE +/-ENE (EXTERNAL NODAL EXTENSION)

NZ - Mestezzais in a single ipolateral (hyph node, 3 cm or less in greater dimension and ENE-positive in more than 2 cm, but not more than 5 cm, but not proper data 6 cm is greater, depending and ENE-negative, or mestezzais in multiple ipolateral hypoth nodes, note more than 6 cm in greatest difference in 6 ENE-negative, or mestezzaig in biolateral or constructed layers nodes, note

N2 a-Metaztatis in a single ipolisteral or contralisteral lymph node 3 cm or less in greatest dimension and ENE-positive; or metaztasis in a single jugislatural lymph node more than 3 cm but not more than 6 cm in greatest dimension and ENE-engitive

N2b-Messessis in a single ipolisteral or contraliseral lymph node 3 cm or less in greatest dimension and ENE-polities; or messessis in a single systematic lymph node more than 3 cm but not not retain 5 cm in greatest dimension and ENE-polities; negative

N2c-Metastasis, in blazaral or contralaseral lymph nodes, none more than 6 cm in greatest dimension and ENE-negative

N3 - Meassasis in a lymph node more than 6 cm in greatest dimension and ENE-negative, or metastasis in a single lipidateral lymph node more than 3 cm in greatest dimension and ENE-positive, or medicates in multiple lipidateral, contralateral, or bitsteral lymph nodes, with any ENE-positive

NSb-Metastasis in a single iguilateral node more than 3 cm in greatest dimension and ENE-positive; or metastasis in multiple ipulateral, contralateral, or bilateral lymph nodes, with any ENE-positive

### STAGING BASED ON TNM

Stage O: Tis, NO, MO TI, NO, MO Stage I: Stage II: T2, NO, MO Stage III: T3, NO,MO TI, <mark>NI</mark>, MO T2, NI, MO T3, NI, MO Stage IVA: T4, NO, MO T4, NI, MO T, N2, MO Stage IVB: T, N3, MO Stage IVC: T,N MI

### TUMOR BOARD

- A multi-disciplinary meeting involving Otolaryngologist, Radiation Oncologist, Hematology/Oncologist, Radiologist, Pathologist, Oncology RN, Palliative Care, Dental, Dietitian,
- Establishing agreement across disciplines on plan for type and timing of treatment for curative intent loco-regional control and palliation (if needed). Tumor boards allow for implementation of chinical practice guidelines and may help capture cases for clinical tractice guidelines and may help capture cases for clinical tractice.



### TUMOR BOARD

- Pathologist:
  Pathologist:
  Palliative Care MD:
  Oncology RN;
  Auxillary Staff: attendance—SLP/RD/PA/NP

SLP: Role depends on facility— mostly educational for SLP in some cases it as education apportunity to facilitate decision and string of treatment (swallow reliable, current dephage lastics) and or sister with providing input on functional status.

"Hopic or swallow functioning may help drive surgical is non-surgical treatment on it contributes to overall functional status.

TUMOR BOARD	
Cases presented:  i) New cancer case 2) Recurrent cancer case	
Treatment failure case  Re-presentation of post-surgical case with complex tumors with high risk histopathological features.  **High risk features include:  **High risk features include:	
ENE—atta nodulor estemino UVI—upplo venculor gread PNI—Perincural Invasión	
PRESENT PLAN TO THE PATIENT	
Patient/family educated on the proposed tumor board plan Patient may want non-surgical vs. surgical option. Educate patient on risk/benefits and realities of treatment.  Patient always has a right to choose to treat or	
not	
PRE-TREATMENT/PRE-OP TEAM	

### DENTAL REFERRAL

- Irradiation immediately puts the patient with head and neck cancer at high risk for treatment-related complications including dry mouth (xerostomia), oral infections, oral muscle fibrosis, and jawbone destruction (osteoradionecrosis).
- Attention is needed to unaddressed periodontal issues and unresolved dental needs before immunosuppression begins
- dental treatment and prophylaxis (fluoride therapy) attention to unaddressed periodontal issues and unresolved dental needs before immunosuppression begins.
- Dental extraction of any un restorable, abscessed, or periodontally diseased teeth in the field of radiation therapy



### HEAD AND NECK RADIATION ONCOLOGIST

- Educated patient on non-surgical options for definitive treatment of tumor if appropriate.
- Educated patient on need for post-operative role of Radiation therapy; recommended regimen and risk factors.
- $^{\ast}$  Discuss standing treatment protocol ( 6 weeks; daily) vs. Clinical trial options.
- Discuss expectations for prognosis and radiation treatment effects (toxicities).
- Timing: standard 6 week treatment window for definitive vs. post-op.



### REGISTERED DIETITIAN REFERRAL (RD)



- Testing and evaluation for nutritional shortcomings or areas of risk.

  A discussion about planning and the setting of nutritional goals

  Simple, practical layer and divice to help estimates schieve their nutritional needs on a daily basis.

  Advice on ways to deal with weight loss, fisigue, and mausea brought on by illness or treatment deel effects.
- size emercs

  Personalized guidelines based on the patients biological needs and unique circumstances

  Plans for families or caregivers in support of the patient's nutritional needs

  Recipes, lists of foods, dietary supplements, and vitamins
- oncology dietitian specializes in helping cancer patients and their caregivers develop a plan for good nutrition. By achieving good overall health, proper nutrition can help reduce the risk of cancer, keep patients health
- Assist with management of non-oral nutrition (when appropriate) if feeding tube is already present or if placement of feeding tube is anticipated.





	1	
SPEECH LANGUAGE PATHOLOGIST		
Evaluate current verbal and written communication skills home situation and new		
<ul> <li>Evaluate current verbal and written communication skills home situation and new learning skills.</li> <li>Assess general understanding of upcoming surgery and emotional state. Offer option for Larrygectomy visitor</li> </ul>		
<ul> <li>Review post-anatomy changes impacting voicing; swallowing and new neck breather status (visual aid)</li> </ul>		
<ul> <li>Review discuss expectations for timing and events related to inpatient hospitalization and SLP role (acute care)</li> <li>Review life-style changes, neck breather status and timing for return to daily living.</li> </ul>		
<ul> <li>Demonstrate options for alaryngeal communication options and initiate electro-larynx training if patient willing.</li> <li>Demonstrate TEP voicing technique (video) sample prostheses (demo model) and discuss SLP role with TEP management.</li> </ul>		
discuss SLP role with TEP management.  Educate and train regarding role of HME system  Offer support encouragement and education as needed		
Oner support, encouragement and education as needed		
SPEECH LANGUAGE PATHOLOGIST		
Clinical issues involved in Salvage Laryngectomy		
Prolonged NPO period		
Possibility of primary vs. secondary TEP procedure		
Potential for more complex reconstruction required with		
Post-operative HME protocol and importance of pursuing HME system		
CASE STUDIES		